Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism; D002247:Carbon Isotopes; D002850:Chromatography, Gel; D002855:Chromatography, Thin Layer; D002986:Clinical Trials as Topic; D004273:DNA, Neoplasm / Q000096:biosynthesis; D005260:Female; D006207:Half-Life; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D011725:Pyridines / Q000009:adverse effects / Q000378:metabolism; D013460:Sulfur Isotopes; D013882:Thiosemicarbazones / Q000009:adverse effects* / Q000097:blood / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D014316:Tritium
D000970:Antineoplastic Agents; D002247:Carbon Isotopes; D004273:DNA, Neoplasm; D011725:Pyridines; D013460:Sulfur Isotopes; D013882:Thiosemicarbazones; D014316:Tritium; D013936:Thymidine